Avant, Ainnova Plan Merger to Boost AI Health Platform

Generative AI is beginning to reshape global healthcare delivery, as companies blend machine learning with clinical workflows to accelerate diagnostics and improve patient care. Among the emerging players is Avant Technologies, which is expanding its footprint through the proposed acquisition of its joint venture partner Ainnova Tech.

The move would consolidate the two companies under the Ai-nova Acquisition Corp. (AAC) umbrella, ahead of a US Food and Drug Administration (FDA) pre-submission meeting scheduled for July. The companies aim to streamline operations, reduce redundancies, and bolster their regulatory pathway as they prepare for US market entry.

“This merger simplifies our roadmap to market and creates value for our shareholders and global partners,” says Vinicio Vargas, CEO, Ainnova.

At the center of Avant’s strategy is Vision AI, a non-invasive clinical screening platform that uses retinal imaging, vital signs, and machine learning algorithms to detect early signs of chronic diseases. These include diabetic retinopathy, cardiovascular conditions, liver and kidney disease, and type 2 diabetes. According to NIH-cited research, the technology has demonstrated more than 90% sensitivity in early detection.

Unlike many AI healthcare ventures, Vision AI is already active in clinical settings. It is being deployed in Latin American countries, including Mexico, Chile, and Brazil, where it is integrated into real-world healthcare workflows. These pilot programs are providing both performance data and critical user feedback, allowing for iterative product refinement.

“This reflects our dual approach,launching in lower-regulation markets to accelerate deployment, while concurrently pursuing FDA clearance in the United States,” said Vargas.

AAC recently expanded Vision AI’s capabilities by adding four new diagnostic algorithms. These were trained on a dataset of more than 2.3 million clinical cases, broadening the platform’s capacity to screen for a wider range of chronic health conditions.

The global market for AI in healthcare is expected to grow significantly. MarketsandMarkets projects the sector will reach more than US$110 billion by 2030, growing at a compound annual rate of 38.6%. Accenture estimates that AI could contribute an additional US$461 billion in value to the healthcare sector by 2035.